White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
CORAL LABORATORIES LTD. (CORALAB) currently trades at ₹600.00, while our model-based Fair Value estimate is ₹468.58, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹794.23 per share, and 5 of the 15 models we run sit above the ₹600.00 price.
Bear case: the Earnings-Based group reads lowest at ₹265.05, and 10 of the 15 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹450.99 (bear) to ₹508.79 (bull), the price of ₹600.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
CORAL LABORATORIES LTD. reported revenue of ₹859M in FY2026 versus ₹732M in FY2022, a compound +4.1%/yr. Reported net income was ₹164M in FY2026, compounding +16.0%/yr from FY2022.
Key figures
Market cap ₹2.1B (≈ $22.8M) Micro · P/E ratio 11.2 · P/S ratio 2.22 · EPS (TTM) ₹53.76 · Dividend yield 0.3% · Net margin 19.9% · Return on equity 8.0% · Return on assets (EBIT) 5.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 66% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −22%, CORALAB screens richer than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹32.76 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income
₹450.99
₹468.58
₹507.04
76
EPV
₹235.77
₹265.05
₹289.05
74
ROIC Compounder
₹235.77
₹265.05
₹289.05
72
All 15 models by family
Earnings-Based
Graham-Dodd
₹311.80
₹664.43
₹843.12
66
PEG = 1.0
₹127.80
₹182.57
₹237.34
57
EPV
₹235.77
₹265.05
₹289.05
74
Dividend Discount
Gordon GGM
₹10.91
₹15.14
₹18.87
69
DDM Multi-Stage
₹10.91
₹14.51
₹17.92
67
Multiples
P/E Multiple
₹756.57
₹1,009
₹1,261
63
P/S Multiple
₹584.62
₹779.49
₹974.37
58
P/B Multiple
₹302.91
₹403.88
₹504.85
55
EV/EBIT
₹458.41
₹613.97
₹769.53
66
EV/EBITDA
₹438.85
₹587.89
₹736.93
67
EV/Revenue
₹324.81
₹467.56
₹610.31
53
Asset-Based
NCAV (Graham)
₹268.64
₹407.03
₹508.79
54
Economic Profit
Residual Income
₹450.99
₹468.58
₹507.04
76
ROIC Compounder
₹235.77
₹265.05
₹289.05
72
Growth Earnings
Growth-Adj P/E
₹555.96
₹794.23
₹1,032
67
Open the full fair value analysis →
Overall quality
49/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
45
How much profit the company makes from its sales and capital
Quality Growth
31
Are margins and returns getting better?
Cashflow
24
Do the profits arrive as real cash?
Financial strength
80
Debt, balance sheet and risk of trouble
Investment
30
Does it invest with discipline instead of growing at any price?
Low Volatility
53
How calm the share price moves, does not count
Price momentum
64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
64
Distance to the 52-week high, does not count
New shares
82
Buys back shares or issues new ones?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is CORAL LABORATORIES LTD. (CORALAB) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of ₹468.58 versus a price of ₹600.00, about 22% lower (overvalued).
What is the fair value of CORALAB?
Our model-based fair value for CORAL LABORATORIES LTD. is ₹468.58 (as of Nov 13, 2026), built from audited fundamentals. The current price: ₹600.00.
What is the quality score of CORALAB?
CORAL LABORATORIES LTD. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CORAL LABORATORIES LTD. (CORALAB)?
Our model-based price target is the fair value of ₹468.58 (as of Nov 13, 2026) from 15 valuation models. Cautious scenario ₹450.99, optimistic scenario ₹508.79. It is a calculation from audited fundamentals, not an analyst target.
What is the CORAL LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹468.58, about 22% lower versus a price of ₹600.00 (overvalued). Cautious scenario ₹450.99, optimistic scenario ₹508.79. The calculation is refreshed regularly with new filings.
What is the revenue of CORAL LABORATORIES LTD. (CORALAB)?
CORAL LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹967M (latest available figure, as of Nov 13, 2026).
Does CORAL LABORATORIES LTD. pay a dividend?
CORAL LABORATORIES LTD. currently shows a dividend yield of 0.33% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of CORAL LABORATORIES LTD. (CORALAB) and when is the ex-dividend date?
CORAL LABORATORIES LTD. pays a dividend of ₹2.00 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Sep 22, 2026. The payout ratio is 3.7% of earnings. Our assessment: Token dividend. At a yield of 0.3% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.3% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of CORAL LABORATORIES LTD. (CORALAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CORAL LABORATORIES LTD. it is ₹468.58 per share (as of Nov 13, 2026), against a price of ₹600.00. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is CORAL LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Nov 13, 2026, CORALAB trades above its calculated fair value: price ₹600.00, fair value ₹468.58, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CORALAB?
No. The price is what the market pays today (₹600.00); the fair value is what the company's own numbers justify (₹468.58). For CORAL LABORATORIES LTD. the two are ₹131.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is CORAL LABORATORIES LTD. worth?
The market values CORAL LABORATORIES LTD. at about ₹2.1B (market capitalisation, as of Nov 13, 2026). Per share that is ₹600.00; our models calculate a fair value of ₹468.58 per share.
What do the bullish and bearish scenarios say about CORALAB?
Our models span a range for CORAL LABORATORIES LTD.: cautious scenario ₹450.99, base ₹468.58, optimistic ₹508.79 per share (as of Nov 13, 2026, price ₹600.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CORALAB?
CORAL LABORATORIES LTD. trades at a price-to-earnings ratio of 11.2 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹468.58 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2019 to 2026), reported earnings: 9.3. Other multiples: P/B 1.0, P/S 2.2, EV/EBITDA 11.6.
How solid is the balance sheet of CORAL LABORATORIES LTD. (CORALAB)?
Balance-sheet figures for CORAL LABORATORIES LTD. (as of Nov 13, 2026): return on equity 8.0%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is CORALAB from its 52-week high?
CORAL LABORATORIES LTD. trades at ₹600.00, about 10% below its 52-week high of ₹665.15 and 66% above the low of ₹362.05 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹468.58 is for.
Which stocks are comparable to CORAL LABORATORIES LTD.?
From the same area (Healthcare) we also value Anuh Pharma Limited, GENNEX, BERLDRG, Eli Lilly and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CORAL LABORATORIES LTD. stock attractive at the current price?
The data as of Nov 13, 2026: price ₹600.00, calculated fair value ₹468.58 (−22%), Quality Score 49/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CORALAB calculated?
We run CORAL LABORATORIES LTD. through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹468.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. CORAL LABORATORIES LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of CORAL LABORATORIES LTD. (CORALAB)?
The closing price on Nov 17, 2026 was ₹600.00. Our model-based fair value is ₹468.58, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CORAL LABORATORIES LTD. right now?
The price sits above even our optimistic bull case (₹508.79). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (₹450.99 to ₹508.79), unusually little disagreement for a valuation.
Key figures of CORAL LABORATORIES LTD.
How large is the market capitalisation of CORAL LABORATORIES LTD. (CORALAB)?
The market capitalisation of CORAL LABORATORIES LTD. is ₹2.1B (≈ $22.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CORAL LABORATORIES LTD. (CORALAB)?
The price-to-sales ratio of CORAL LABORATORIES LTD. is 2.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CORAL LABORATORIES LTD. (CORALAB)?
Earnings per share at CORAL LABORATORIES LTD. are ₹53.76 (price ÷ EPS = P/E 11.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CORAL LABORATORIES LTD. (CORALAB)?
The dividend yield of CORAL LABORATORIES LTD. is 0.3% (payout 3.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CORAL LABORATORIES LTD. (CORALAB)?
The net margin of CORAL LABORATORIES LTD. is 19.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CORAL LABORATORIES LTD. (CORALAB)?
The return on equity (ROE) of CORAL LABORATORIES LTD. is 8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CORAL LABORATORIES LTD. (CORALAB)?
On an EBIT basis the return on assets of CORAL LABORATORIES LTD. is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CORAL LABORATORIES LTD. (CORALAB)?
The operating margin of CORAL LABORATORIES LTD. is 16.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CORAL LABORATORIES LTD. (CORALAB)?
Revenue at CORAL LABORATORIES LTD. is growing 57.4% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CORAL LABORATORIES LTD. (CORALAB)?
Earnings per share at CORAL LABORATORIES LTD. are growing 110% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CORAL LABORATORIES LTD. (CORALAB) generate?
The free cash flow of CORAL LABORATORIES LTD. is −₹79.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CORAL LABORATORIES LTD. (CORALAB) carry?
The net debt of CORAL LABORATORIES LTD. is ₹29.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.